1 min read
Selexis CSO to Speak at the Irvine Scientific Exhibit at BPI 2012
Dr. Pierre-Alain Girod Will Present Data on Achieving High Yields with Difficult-to-Express Proteins Using the Selexis...
Dr. Pierre-Alain Girod Will Present Data on Achieving High Yields with Difficult-to-Express Proteins Using the Selexis...
Lubris Achieves Over Gram per Liter of Recombinant Human Lubricin Using Selexis SUREtechnology Platform
Geneva,...
The New Media Improves SURE CHO-M Productivity
Geneva, Switzerland, June 6, 2012 – Selexis SA, a global life sciences...
Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug...
Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug...
Geneva, Switzerland, May 23, 2012 (PRNewswire) – Selexis SA, a global life sciences company for drug discovery, cell...
Geneva, Switzerland, May 15, 2012 (PRNewswire) – Selexis SA, a global life sciences company for drug discovery, cell...
Geneva, Switzerland (PRWEB) April 26, 2011 – Selexis SA, a global life sciences company for drug discovery, cell line...
Geneva, Switzerland (PRWEB) April 19, 2012 – Selexis SA announced today the Company’s co-founder will present data on...
Former Diosynth and Lonza Executive Joins Expanding Leadership Team
Geneva, Switzerland (PRWEB) January 6, 2012 –...
Dr. Igor Fisch to Present in the Private Company Track
Geneva, Switzerland (PRWEB) January 5, 2012 – Selexis SA...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.